Coherus Biosciences | CHRS - Actif À Court Terme





Actif À Court Terme Changement Date
AbbVie USD 33.53B 4.47B 2026-03
Acadia Pharmaceuticals USD 1.1B 33.9M 2026-03
Akebia Therapeutics USD 243.48M 9.47M 2026-03
ALKERMES USD 1.36B 570.52M 2026-03
Alnylam Pharmaceuticals USD 4.22B 168.65M 2026-03
Amarin USD 626.02M 23.87M 2026-03
Amgen USD 31.48B 2.42B 2026-03
Baxter International USD 6.85B 25M 2026-03
Biogen USD 9.19B 216.3M 2026-03
BioMarin Pharmaceutical USD 4.61B 651.58M 2026-03
Bristol-Myers Squibb USD 27.21B 2.18B 2026-03
Coherus Biosciences USD 206.71M 254.25M 2025-12
Eli Lilly USD 54.84B 794M 2026-03
Fujifilm JPY 1.72T 2.2B 2026-03
Gilead Sciences USD 18.64B 1.25B 2026-03
Ironwood Pharmaceuticals USD 332.29M 58.11M 2026-03
Merck USD 35.02B 8.5B 2026-03
Myriad Genetics USD 312.8M 19.8M 2026-03
Pacira USD 514.96M 33.01M 2026-03
Perrigo USD 2.71B 85M 2026-03
Pfizer USD 42.82B 76M 2026-03
PTC Therapeutics USD 2.25B 19.94M 2026-03
Regeneron Pharmaceuticals USD 18.21B 187.3M 2026-03
Sarepta Therapeutics USD 2.31B 228.06M 2026-03
Teva Pharmaceutical Industries USD 13.71B 236M 2026-03
Vertex Pharmaceuticals USD 11.73B 529.3M 2026-03
Xencor USD 482.85M 116.97M 2026-03
Zoetis USD 6.47B 294M 2026-03